PricewaterhouseCoopers has been running the numbers on deals and dollars in the biopharma industry. And the big accounting firm is echoing a growing lineup of analysts who see that dealmaking in the industry is suffering even as IPOs are booming. But easy access to cash could change things around dramatically in the second half of this year.
In its $1.15 billion buyout of Pearl Therapeutics this week, AstraZeneca bolstered its late-stage drug development with a Phase III inhaled delivery platform to treat respiratory diseases.
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.
Last week FDA staffers came up with a lukewarm review of the efficacy seen in Boehringer Ingelheim's prospective COPD drug olodaterol, but couldn't fault its safety profile. And that seemed to satisfy the panel of outside experts who met to review the drug today, giving it a pass with a lopsided 15-to-1 vote in favor of approval.
Pearl Therapeutics has grabbed a hefty $65 million venture round, enough to bankroll the launch of a key late-stage COPD drug program that--one way or another--will prove transformational for the biotech.
Eyeing the major market for a chronic lung condition, Forest Laboratories ($FRX) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Pearl Therapeutics put its combo LAMA/LABA treatment for COPD--PT003--up against two standard treatments for the lung disease and says it emerged with a commanding lead based on a key method for
The four-year-old Pearl Therapeutics, which was founded by a pair of Nektar execs armed with some in-licensed particle technology that could be used to treat respiratory ailments, has rounded up $69
Pearl Therapeutics has reported results from four studies supporting further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized